CONMED (CNMD) Q1 2026 earnings review
Organic Strength Masked by GI Exit
CONMED reported a 1.3% decline in Q1 2026 revenue, driven entirely by a $15.5 million headwind from its strategic exit of the gastroenterology (GI) business. Excluding this, underlying organic growth was strong enough for management to raise full-year organic constant-currency revenue guidance to 5.0%-6.5%. However, profitability is taking a planned step back. Adjusted EPS fell 6% YoY to $0.89, and full-year EPS guidance was maintained at $4.30-$4.45, reflecting higher anticipated interest expenses from upcoming debt refinancing.
🐂 Bull Case
After resolving FY25 supply chain bottlenecks, the Orthopedic Surgery segment accelerated, delivering 6.8% YoY reported growth. This validates the strength of key products like BioBrace.
Management raised organic constant-currency revenue guidance to 5.0%-6.5%. The underlying demand for AirSeal, Buffalo Filter, and soft tissue repair remains robust.
🐻 Bear Case
Despite a 100 bps expansion in adjusted gross margin, adjusted operating margin contracted from 14.1% to 13.1%. Heavy investments in R&D and SG&A are outweighing the gross margin gains.
Adjusted EPS is declining YoY, hampered by the lost GI revenue, tariff impacts carried over from FY25, and elevated interest expenses.
⚖️ Verdict: ⚪
Neutral. The decision to cut the low-margin GI segment makes top-line numbers look ugly but is structurally sound. However, the drop in operating margins and looming debt refinancing costs mean the bottom line will struggle to match organic top-line momentum this year.
Key Themes
Orthopedic Soft Tissue Repair Rebound
Accelerating. The Orthopedic Surgery segment grew 6.8% YoY to $147.7M (up 4.5% in constant currency). This marks a solid continuation of the recovery seen late in FY25 after severe supply chain constraints were resolved, allowing reps to push higher-value products like BioBrace.
Gross Margin Mix Shift
Stable to Accelerating. Adjusted gross margin expanded 100 basis points YoY to 57.4%. This is a direct, positive consequence of shedding the lower-margin gastroenterology business to focus strictly on higher-margin minimally invasive platforms like AirSeal and smoke evacuation.
Favorable Macro FX Tailwinds
The company upgraded its foreign exchange macro assumptions. The updated FY26 revenue outlook now incorporates 40 to 50 basis points of favorable FX impact, up from prior assumptions of 0 to 50 basis points, providing a slight cushion against international market volatility.
Operating Leverage Contraction
Adjusted operating margin fell sharply from 14.1% in 25Q1 to 13.1% in 26Q1. While gross margins improved, adjusted SG&A climbed to 40.0% of sales (up from 38.7%), and R&D increased to 4.8% of sales. The company is spending heavily to fuel its core drivers, but it is currently destroying operating leverage.
Debt Refinancing Caps EPS Upside
Despite raising the organic revenue guide and citing 'stronger underlying operating performance,' management merely maintained Adjusted EPS guidance. The stated reason: higher-than-anticipated interest expense due to a planned 2026 debt refinancing. Debt costs will swallow the operational outperformance.
International Capital Placements Sputter
Reversing. Capital Products revenue grew 4.6% globally, but the underlying geographic mix is worrying. International Capital Products revenue declined 4.8% YoY in constant currency, suggesting uneven global hospital cap-ex budgets and potential delays in international robotic integration.
GI Divestiture Execution
The exit from the gastroenterology portfolio is moving rapidly. Management slashed the FY26 revenue expectation from these products to $14.5M-$17.5M (down from $21M-$25M). In Q1 alone, the exit created a massive $15.5M revenue gap, heavily distorting General Surgery optics.
Other KPIs
Decelerating. Down 2.3% YoY (-3.9% CC). This historically steady recurring revenue stream was artificially pulled negative by the GI product exit. Stripping that out, core consumables associated with AirSeal and Orthopedics remain structurally sound.
Stable. Up 4.7% as reported (+1.0% CC). Even absorbing a $0.3M hit from the GI exit, OUS markets showed resilience, outperforming the heavily impacted US market (-5.8% YoY).
Guidance
Accelerating. Raised from previous 4.5% - 6.0%. This excludes the GI business divestiture. It proves management's confidence in the underlying volume momentum for their core orthopedic and general surgery focus areas.
Stable. Narrowed and slightly increased at the bottom end from prior $1.345 - $1.375 billion. At the midpoint ($1.3625B), this implies a slight 0.9% YoY contraction compared to FY25's $1.375 billion, mechanically driven by the $78M+ YoY drop in GI sales.
Reversing. Maintained from prior guidance. The midpoint ($4.375) represents a 4.7% YoY decline from FY25's $4.59. The contraction is a mix of stranded overhead from the GI exit, lingering tariff absorption, and the newly announced debt refinancing interest burdens.
Key Questions
Debt Refinancing Details
With the 2026 debt refinancing explicitly called out as an EPS headwind, what are the expected interest rate parameters and total debt levels assumed in the reaffirmed guidance?
Margin Floor on the Core Business
Adjusted operating margins dropped to 13.1% despite gross margin expansion. When will the heavy SG&A and R&D investments begin to yield operating leverage on the newly focused core portfolio?
International Capital Weakness
International Capital Products declined nearly 5% in constant currency. Is this a timing issue with distributor stocking, or a broader signal of hospital cap-ex caution outside the U.S.?